The Value of Medicines: A Crucial but Vague Concept

PharmacoEconomics

Volumn 34, Issue 12, 2016, Pages 1227-1239

  Antoñanzas, Fernando ^a   Terkola, Robert ^b,c   Postma, Maarten ^c,d  

^a UNIVERSITY OF LA RIOJA   (Spain)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE; HUMAN; MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST; DECISION SUPPORT SYSTEM; ECONOMICS; EUROPE; HEALTH CARE DELIVERY; MEDICAL TECHNOLOGY; PROCEDURES;

DRUG;

BIOMEDICAL TECHNOLOGY; COSTS AND COST ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; EUROPE; HUMANS; PHARMACEUTICAL PREPARATIONS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84979248824     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0434-8     Document Type: Review

References (80)

1. Vogler S, Habl C, Bogut M, Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J. 2011;52(2):183–97.
2. Levaggi R, Pertile P. Drug prices and incentives to innovation by the pharmaceutical industry. In: Babar Z-U-D, editor. Pharmaceutical prices in the 21st century. Cham: Springer International Publishing; 2015. p. 389–401.
3. McGuire A, Raikou M, Kanavos P. Pricing pharmaceuticals: value based pricing in what sense? 2008. http://apps.who.int/medicinedocs/documents/s20973en/s20973en.pdf. Accessed 7 May 2015.
4. Hughes DA. Value-based pricing: incentive for innovation or zero net benefit? Pharmacoeconomics. 2011;29(9):731–5.
5. Miller DW. Value-based pricing examples of healthcare system reforms from the UK and US and implications for industry. Pharm Med. 2012;26(4):217–22.
6. Hao Y. Health technology assessment and value-based pricing in Germany, the United Kingdom and France: recent developments and implications. Value Health. 2013;16(3):A261.
7. Porter M. What is value in health care? N Engl J Med. 2010;363:2477–81.
8. Weinstein MC. A QALY is a QALY—or is it? J Health Econ. 1988;7(3):289–90.
9. Stewart G, Eddowes L, Hamerslag L, Kusel J. The impact of NICE’s end-of-life threshold on patient access to new cancer therapies in England and Wales. Value Health. 2014;17(3):A6.
10. Scottish Medicines Consortium. SMC modifiers used in appraising new medicines. 2012. https://www.scottishmedicines.org.uk/About_SMC/Policy_statements/SMC_Modifiers_used_in_Appraising_New_Medicines. Accessed 25 Apr 2016.
11. Zorginstituut Nederland. Kosteneffectiviteit in de praktijk. 2015. https://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/rapporten-en-standpunten/2015/1506-kosteneffectiviteit-in-de-praktijk/1506-kosteneffectiviteit-in-de-praktijk/Kosteneffectiviteit+in+de+praktijk.pdf. Accessed 25 Apr 2016.
12. Paris V, Belloni A. Value in pharmaceutical pricing. OECD health working papers. 2013. http://www.oecd-ilibrary.org/social-issues-migration-health/value-in-pharmaceutical-pricing_5k43jc9v6knx-en. Accessed 25 Apr 2016.
13. Goldman D, Lakdawalla D, Philipson TJ, Yin W. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ. 2010;19(10):1109–16.
14. Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948–64.
15. Shah KK, Tsuchiya A, Wailoo AJ. Valuing health at the end of life: an empirical study of public preferences. Eur J Health Econ. 2014;15(4):389–99.
16. Brazier J, Rowen D, Mukuria C, Whyte S, Keetharuth A, Hole AR, et al. Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey. Policy Research Unit in Economic Evaluation of Health and Social Care Interventions. 2013. http://www.eepru.org.uk/EEPRU%20VBP%20survey%20DP.pdf. Accessed 14 Apr 2016.
17. Wallace LS. A view of health care around the world. Ann Fam Med. 2013;11(1):84.
18. Mihályi P. The 2007–2009 reform of the hungarian health insurance system. www.eum.hu/download.php?docID=1318. Accessed 13 March 2016.
19. Snyder SR, Mitropoulou C, Patrinos GP, Williams MS. Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity. Public Health Genomics. 2014;17(5–6):256–64.
20. Cormier JN, Cromwell KD, Pollock RE. Value-based health care: a surgical oncologist’s perspective. Surg Oncol Clin N Am. 2012;21(3):497–506.
21. Williams P, Mauskopf J, Lebiecki J, Kilburg A. Using multicriteria decision analysis during drug development to predict reimbursement decisions. J Mark Access Health Policy. 2014;2:25270.
22. McCabe C, Husereau D. Personalized medicine and health care policy: from science to value. Genome Canada. 2014. http://www.genomecanada.ca/medias/pdf/en/PersonalizedMedecine_Policy-Directions-Brief.pdf. Accessed 14 Apr 2016.
23. HTAi Policy Forum. HTA and value: assessing value, making value-based decisions, and sustaining innovation. 2013. http://www.htai.org/fileadmin/HTAi_Files/Policy_Forum_Public/HTAi_Policy_Forum_Background_Paper_2013.pdf. Accessed 14 Apr 2016.
24. Camps-Walsh G, Aivas I, Barratt H. Improving UK patient outcomes: how can value-based pricing improve access and adoption of new treatments? 2009. http://www.2020health.org/dms/2020health/downloads/reports/2020vpcdoc-sep09.pdf. Accessed 14 Apr 2016.
25. Henshall C, Schuller T. HTAi Policy Forum. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29(4):353–9.
26. Oortwijn W. Facts and values, HTA and ethics: two cultures or two aspects of the same thing? HTAi, 11th Annual Meeting, 2014. http://www.htai.org/fileadmin/HTAi_Files/ISG/Ethics/Preconf_Ethics_Wija_Oortwijn0906.pdf. Accessed 14 Apr 2016.
27. Rotter J, Foerster D, Bridges J. The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):711–23.
28. Hughes-Morgan D, Tovey H. Cancer patients’ views on government plans to introduce value-based pricing for medicines. A report for Cancer Research UK. 2011. http://www.cancerresearchuk.org/sites/default/files/policy-cancer-drugs-value-based-pricing-2011.pdf. Accessed 14 Apr 2016.
29. Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH. International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics. 2010;28(10):813–30.
30. Kanavos P, Manning J, Taylor D, Schurer W, Checchi K. Implementing value-based pricing for pharmaceuticals in the UK. 2010. http://www.2020health.org/dms/2020health/downloads/reports/2020vpblow27-04.pdf. Accessed 14 Apr 2016.
31. Bouvy J, Vogler S. Pricing and reimbursement policies: impacts on innovation. WHO Collaborating Centre for Pharmaceutical Policy and Regulation. 2013. http://www.who.int/medicines/areas/priority_medicines/BP8_3_pricing.pdf. Accessed 14 Apr 2016.
32. Brousselle A, Lessard C. Economic evaluation to inform health care decision-making: promise, pitfalls and a proposal for an alternative path. Soc Sci Med. 2011;72(6):832–9.
33. Schlander M, Garattini S, Kolominsky-Rabas P, Nord E, Persson U, Postma M, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Value Health. 2013;16(7):A324.
34. Brazier PJ, Durand A, Tierney R, Kelly S. Discontinuities between Health Technology Assessment (HTA) and health care service objectives of the NHS. Value Health. 2014;17(7):A450.
35. Stafinski T, Menon D, Davis C, McCabe C. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. Clinicoecon Outcomes Res. 2011;3:117–86.
36. Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health. 2012;15(8):1172–81.
37. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. https://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf. Accessed 14 Apr 2016.
38. Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ. 2010;11(2):195–203.
39. Toumi M. MCDA utilization for public health decision process. ISPOR 4th Latin America Conference. 2013. http://www.ispor.org/conferences/BuenosAires0913/presentations/Amgen-SymposiumBuenosAires-Toumi.pdf. Accessed 14 Apr 2016.
40. Manning J. Priority-setting processes for medicines: the United Kingdom, Australia and New Zealand. J Law Med. 2011;18(3):438–52.
41. Hawkins N, Scott D, Moore P. A review of different approaches proposed for value based pricing. Value Health. 2012;15:A32.
42. Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics. 2014;32(4):345–65.
43. Sorenson C, Drummond M, Kanavos P. Ensuring value for money in health care. The role of health technology assessment in the European Union. 2008. http://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdf. Accessed 6 May 2015.
44. Kanavos P, Nicod E, Espin J, van den Aardwerg S. Short- and long-term effects of value-based pricing vs. external price referencing. 2010. http://whocc.goeg.at/Literaturliste/Dokumente/FurtherReading/Short-%20and%20long-term%20effect%20of%20value-based%20pricing.pdf. Accessed 14 Apr 2016.
45. Haute Autorite de Sante. A methodological guide. Choices in methods for economic evaluation. 2012. http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/choices_in_methods_for_economic_evaluation.pdf. Accessed 14 Apr 2016.
46. Kerr A, Todd C, Ulyate K, Hebborn A. A comparison of international health technology assessment systems– does the perfect system exist? ISPOR 17th Annual European Congress. 2014. http://www.ispor.org/research_pdfs/48/pdffiles/PHP221.pdf. Accessed 14 Apr 2016.
47. Gulacsi L, Rotar AM, Niewada M, Loblova O, Rencz F, Petrova G, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ. 2014;15(Suppl 1):S13–25.
48. Persson U, Svensson J, Pettersson B. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2012;10(4):217–25.
49. Caro JJ, Nord E, Siebert U, McGuire A, McGregor M, Henry D, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ. 2010;19(10):1117–27.
50. College voor zorgverzekeringen. A background study on the ‘cost-effectiveness’ package principle for the benefit of the appraisal phase in package management. http://jannetvb.home.xs4all.nl/busschbach/manuscripts/2010%20Engelse%20Vertaling%20CVZ%20rapport%20ACP%20pakketprincipe%20en%20KEA.pdf. Accessed 7 May 2015.
51. Camps-Herrero C, Paz-Ares L, Codes M, Lopez-Lopez R, Anton-Torres A, Gascon-Vilaplana P, et al. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists. Clin Transl Oncol. 2014;16(10):914–20.
52. Simoens S, Dooms M. How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther. 2011;36(3):249–56.
53. Hawryluk EA, Malhotra M, Chawla V, Doyle J. PRM160 a new value-based pricing framework for the optimal pricing of pharmaceutical assets. Value Health. 2012;15(7):A489–90.
54. Hulshof JAM. Sustainable health care systems: the role of therapeutic value and value based pricing. Value Health. 2014;17(7):A452.
55. Healy P, Pugatch M. Capturing value: why dynamic efficiency should be considered in the pricing and reimbursement of medicines. Stockholm: Stockholm Network; 2012.
56. ®) in Sweden. Appl Health Econ Health Policy. 2010;8(6):377–86.
57. Duerden M. From a cancer drug fund to value based pricing of drugs. BMJ. 2010;341:c4388.
58. Roberts G. Value based pricing: one threshold too far for the United Kingdom. Value Health. 2011;14:A241.
59. Roberts G. Using the CEAC for value based pricing: don’t change the goalposts [abstract no. PHP157]. Value Health. 2011;14:A361.
60. Kanavos P, Angelis A. Multiple criteria decision analysis for value based assessment of new medical technologies: a conceptual framework. 2013. http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/LSEHealthworkingpaperseries/LSEH-WP33_final.pdf. Accessed 7 May 2015.
61. van Til J, Groothuis-Oudshoorn C, Lieferink M, Dolan J, Goetghebeur M. Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework. Cost Eff Resour Alloc. 2014;12(22):1–11.
62. Broekhuizen H, Groothuis-Oudshoorn CG, van Til JA, Hummel JM, IJzerman MJ. A review and classification of approaches for dealing with uncertainty in multi-criteria decision analysis for healthcare decisions. Pharmacoeconomics. 2015;33(5):445–55.
63. Marsh K, Dolan P, Kempster J, Lugon M. Prioritizing investments in public health: a multi-criteria decision analysis. J Public Health (Oxf). 2013;35(3):460–6.
64. Adunlin G, Diaby V, Xiao H. Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis. Health Expect. 2015;18(6):1894–905.
65. Adunlin G, Diaby V, Montero AJ, Xiao H. Multicriteria decision analysis in oncology. Health Expect. 2015;18(6):1812–26.
66. Diaby V, Goeree R. How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):81–99.
67. Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Assessing the value of treatments for rare diseases using an Mcda-based approach: methodological and ethical foundations of criteria selection and framework development. Value Health. 2014;17(3):A7.
68. Endrei D, Molics B, Agoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17(4):487–9.
69. NHS England. Standard operating procedures: The Cancer Drugs Fund (CDF) guidance to support operation of the CDF in 2014-15. 2014. http://www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf. Accessed 14 Apr 2016.
70. Salimi T, Lehner JP, Epstein RS, Tunis SR. A framework for pharmaceutical value-based innovations. J Comp Eff Res. 2012;1(1 Suppl):3–7.
71. Wei DH, Hawker GA, Jevsevar DS, Bozic KJ. Improving value in musculoskeletal care delivery: AOA critical issues. J Bone Joint Surg Am. 2015;97(9):769–74.
72. Utz KS, Hoog J, Wentrup A, Berg S, Lämmer A, Jainsch B, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263–75.
73. Huynh TK, Østergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–9.
74. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9.
75. Bach PB. New math on drug cost-effectiveness. N Engl J Med. 2015;373(19):1797–9.
76. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–77.
77. NCCN unveils evidence blocks for CML and multiple myeloma. https://www.nccn.org/about/news/newsinfo.aspx?NewsID=546. Accessed 30 June 2016.
78. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA Statement on cost/value methodology in clinical practice guidelines and performance measures. A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(21):2304–22.
79. Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing: can regulators influence affordability? N Engl J Med. 2016;374(19):1807–9.
80. Heintz E, Gerber-Grote A, Ghabri S, Hamers FF, Rupel VP, Slabe-Erker R, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. Pharmacoeconomics. 2016;34(1):59–76.